Plain-English translation of NCT06043466 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new cancer treatment called C-13-60, which uses your own immune cells that have been specially engineered in a laboratory to recognize and fight cancer cells. The treatment is being tested in patients with advanced cancers—including colorectal, esophageal, gastric, pancreatic, lung, breast, and bile duct cancer—that have stopped responding to standard treatments. Researchers will gradually increase the dose of the medication to find the safest and most effective amount.
Standard cancer treatments often stop working over time, leaving patients with few options. This study explores whether this new cell-based treatment can help patients whose cancers no longer respond to chemotherapy, targeted drugs, or immunotherapy.
You likely qualify if…
You likely don't qualify if…
You will receive preparation chemotherapy 1–5 days before receiving infusions of the engineered immune cells through an intravenous line. The study uses a 'dose-escalation' approach, meaning the first participants receive a smaller dose, and if it is safe, later participants receive higher doses. Your safety will be closely monitored for at least 28 days after each infusion, with regular clinic visits and blood tests to watch for side effects and how well the treatment is working.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China